← 홈

Antibody · HER2+ 유방암

157개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 157개
AntibodyAHotstaleRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 1044상태 ACTIVE
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 224상태 DISCONTINUED
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 134상태 RECRUITING
AntibodyBHotInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 4.5%임상시험 123상태 RECRUITING
AntibodyBHotBiologicstaleRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5
효능 ORR 91.2%임상시험 113상태 RECRUITING
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
AntibodyCstaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
AntibodyCJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 78상태 RECRUITING
AntibodyAkeso-drivenPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#인기#항체+5
임상시험 65상태 RECRUITING
AntibodyAkesogovitecan), and chimeric an…Phase 2

Ivonescimab (Ivonescimab)

Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 62상태 RECRUITING
AntibodyRocheDeruxtecan plus Pertuzumab …Phase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#인기#항체+5
효능 ORR 88.6%임상시험 60상태 ACTIVE
AntibodyRocheDM1Phase 2

trastuzumab (Herceptin, Pertuzumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#인기#항체+5
효능 ORR 88.6%임상시험 58상태 RECRUITING
AntibodyRochederuxtecan alone or followe…Phase 3

trastuzumab (Herceptin, Paclitaxel + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 80%임상시험 57상태 RECRUITING
AntibodyMridula George, MDderuxtecan, datopotamab der…Phase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 100%임상시험 49상태 RECRUITING
AntibodyChia Tai Tianqing Pharmaceutica…Phase 2

Penpulimab (Penpulimab)

Advanced Malignant Neoplasm · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+4
임상시험 47상태 ACTIVE
AntibodyJazz Pharmaceuticalsderuxtecan, telisotuzumab v…Phase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 33%임상시험 33상태 ACTIVE
AntibodyQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 27%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 ACTIVE

1 / 8 페이지

← 이전다음 →